Kornimate/medical-research-clean huggingface dataset:
mobilization of stem cells with g-csf and mozobil in patients with end stage liver disease

Conditions: End Stage Liver DIsease

Summary: a phase i trial to study the safety of mobilization of stem cells with g-csf and mozobil in patients with chronic liver disease.

liver cirrhosis in humans represents the end stage of chronic liver injury. supply of "new" stem cells to the liver could regenerate hepatocytes and restore the lost function. delivery of mesenchymal stem cells (mscs) has been shown in animal models and limited clinical trials to result in improved liver disease (meld) score. in preclinical studies we have demonstrated that the combination of g-csf plus mozobil can effectively mobilize both hematopoietic stem cells (hscs) and mscs into the peripheral circulation. while g-csf only mobilizes hscs. the clinical trial will test the safety of treating patients with end stage liver disease with g-csf and mozobil to mobilize mscs into the peripheral circulation.

Eligibility criteria:
inclusion criteria: * patients with a clinical diagnosis of cirrhosis age greater than or equal to 18 years meld score less than or equal to 12 able to provide informed consent hiv and hbsag seronegative platelet count \>50,000, wbc count \> 2,000 no history of malignancy within the last 5 years, except for non-melanoma skin cancer or cervical carcinoma in situ no lesions suspicious for liver cancer on ct and/or mri within prior 4 months exclusion criteria: patients with acute or subacute onset of liver disease patients who have received a liver transplant age \ 12 patients whose meld scores are currently less than or equal to 12 but with history of prior deterioration with meld score \>12 unable to provide informed consent patients with hiv or hbsag seropositivity pregnant or lactating females enrolled in another research protocol any condition that precludes serial follow up patients with history of malignancy within the last 5 years, except for non-melanoma skin cancer or cervical carcinoma in situ any lesions suspicious for liver cancer on ct and/or mri within prior 4 months patients with palpable splenomegaly on physical examination any condition that in the investigators opinion would likely increase the risk of particpation or would likely confound interpretation of the data -
analysis of hyperthermia as a complementary treatment to evidence-based clinical intervention in subjects with carpal tunnel syndrome:

Conditions: Carpal Tunnel Syndrome (CTS); Hyperthermia; Frequency of Therapy

Summary: this project aims to analyze the use of hyperthermia within a treatment protocol for carpal tunnel syndrome (cts), as well as to determine the difference between two and three sessions per week. study participants will be divided into four intervention groups: the first will receive two sessions per week for a period of six months, while the second will receive three sessions per week for the same period. the treatment protocol will consist of therapeutic physical exercise focused on the hand flexor muscles and neural stretching, the application of hyperthermia to the carpal tunnel and adjacent areas, and the use of a night splint. the third and fourth intervention groups will receive the same treatment as mentioned above, but without hyperthermia. the third group will receive three sessions per week, while the second group will receive two sessions per week. two different types of measurement variables will be used: objective variables will be used to measure hand flexor muscle strength and wrist free range of motion. subjective variables will also be used through validated questionnaires covering physical activity, perceived functional limitations, upper limb functional assessment, neuropathic pain, and a visual analogue scale for pain perception.


Eligibility criteria:
inclusion criteria: * have a diagnosis confirmed by performing an electromyography of carpal tunnel syndrome * have not yet received physiotherapy treatment. exclusion criteria: * have undergone surgery. * those who refuse to participate in this study. * patients with muscle atrophy due to cts. * medical conditions that are contraindications for hyperthermia therapy.
probiotics and influenza vaccination response

Conditions: Vaccine Response

Summary: assess efficacy of oral ingestion of a probiotic product on immune function in a population of healthy adult men and women in a clinical vaccination study.


Eligibility criteria:
inclusion criteria: * men and women * age 16 - 65 y and healthy * self-reported regular dutch eating habits as assessed by questionnaire (3 main meals per day) * no influenza vaccination in 2022 * non-smokers * bmi 18.5-28 * adherence to habitual diet * no changes during study period * signed informed consent exclusion criteria: * recent vaccination * acute or chronic illness (e.g., diabetes mellitus) * gastrointestinal disorders (e.g., inflammatory bowel disease) * acute gastroenteritis in the past 2 months * immunodeficiency disorder * use of immunosuppressive drugs (e.g. cyclosporine, azathioprine, systemic corticosteroids, antibodies) * unexplained weight loss or weight gain of \> 3 kg in the 3 months prior to pre-study screening * alcohol or drug abuse * mental status that is incompatible with the proper conduct of the study * history of cancer * use of immune boosting supplements within 4 weeks before screening to be extended \& specified in protocol phase

Keywords: vaccine response seroconversion antibody
humanized car-t cells of anti-bcam and anti-cd19 against relapsed and refractory multiple myeloma

Conditions: Relapsed or Refractory Multiple Myeloma

Summary: this is a single arm, open-label, single center study to evaluate the safety and efficacy of bcma/cd19 car-t cells in patients with bcma+，cd19+ relapsed or refractory multiple myeloma.

cd19 has been extensively evaluated as a therapeutic target for relapsed or refractory multiple myeloma by chimeric antigen receptor t cell therapy,this is a single arm, open-label, single center study to preliminary explore the safety, tolerability and cellular pharmacokinetics of anti-bcma and anti-cd19 car-t cells in the treatment of relapsed or refractory multiple myeloma.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18-70 years old 2. estimated survival time \> 12 weeks 3. relapsed and refractory multiple myeloma were confirmed by physical examination, pathological examination, laboratory examination and imaging 4. chemotherapy failure or recurrent multiple myeloma 5. glutamic-pyruvic transaminase, glutamic oxalacetic transaminase\< 3 fold of normal level 6. bilirubin\<2.0mg/dl 7. karnofsky performance status\>50% at the time of screening 8. adequate pulmonary, renal, hepatic, and cardiac function 9. fail in autologous haemopoietic stem cell transplantation 10. not suitable for stem cell transplantation conditions or abandoned due to conditions 11. free of leukocytes removal contraindications 12. voluntarily join car-t clinical trial ,understand and sign written informed consent exclusion criteria: 1. the patient is a pregnant or breastfeeding woman, or is a woman with a pregnancy plan within six months 2. patients have infectious diseases (such as hiv, active tuberculosis, etc.) 3. the patient is an active hepatitis b or hepatitis c infection 4. feasibility assessment proves that the efficiency of transduction of lymphocyte is below 10% or the lymphocyte cannot be propagated 5. abnormal vital signs 6. subjects with mental or psychological illness who cannot be combined with treatment and efficacy evaluation. 7. highly allergic constitution or history of severe allergies, especially allergy to interleukin-2 8. general infection or local severe infection, or other infection that is not controlled 9. dysfunction in lung, heart, kidney and brain 10. severe autoimmune diseases 11. other symptoms that are not applicable for car-t

Keywords: relapsed and refractory multiple myeloma; car-t
myopia control in children: comparison of defocus incorporated multiple segments® lenses versus atropine 0.05% eyedrops

Conditions: Myopia

Summary: myopia is the most common refractive disorder in the world. many strategies have been developed to control myopia in children. among them, the instillation of low-concentration atropine eyedrops has been proven to be effective in numerous publications. nevertheless, the spreading of atropine use is limited by: (1) its uneven availability, (2) a proportion of children with no or poor response, (3) some issues of long-term compliance (4) the possibility of a rebound effect after treatment cessation. among the non-drug myopia control strategies, corrective lenses including the defocus incorporated multiple segments® (dims®) technology have demonstrated their effectiveness in a previous study (hong kong) when compared to monofocal lenses. the aim of this study is to compare the efficacy of dims lenses alone versus atropine 0.05% eyedrops + monofocal lenses, on the evolution of ocular axial length at 2 years in myopic children.


Eligibility criteria:
inclusion criteria: * diagnosis of myopia - measured under cycloplegia - defined by: 1. a sphere power between -1 and -6 diopters, on at least one of the two eyes 2. and a cylindrical power strictly inferior to 2 diopters 3. and a maximum refractive error strictly inferior to 8 diopters in the flattest axis * not benefiting and never having benefited from a myopia control strategy (orthokeratology, soft defocusing lenses, low concentration atropine eye drops, peripheral defocusing corrective lenses) * written consent of both parents exclusion criteria: * history of genetic disease, or general condition suggesting a syndromic myopia (including an axial length greater than 27 mm) * strabismus * amblyopia defined by a best corrected visual acuity strictly inferior to 10/10 on one of the two eyes * anisometropia defined by a difference of 2 diopters or more between the two eyes (in spherical equivalent) * history of allergy to atropine * history of severe anaphylaxis * optical correction with contact lenses * previous ophthalmologic surgery of the cornea, lens, retina * history of glaucoma or any other chronic ophthalmological disease in the course of treatment (including vernal keratoconjunctivitis)

Keywords: myopia pediatric ophthalmology myopia control defocus incorporated multiple segments (dims) lenses low concentration atropine
ointment therapy and prevention of cannulation-induced superficial phlebitis

Conditions: Phlebitis

Summary: the aim of this study was to determine the effect of clobetasol ointment with nitroglycerin ointment on the prevention of superficial phlebitis caused by cannulation. this clinical trial was conducted on 110 patients admitted to the surgical ward, in three groups of clobetasol, nitroglycerin, and control. the data collection tools included demographic information, information about intravenous treatment and phlebitis measurement scale. in the intervention groups, after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the angio catheter and the site was dressed with sterile gauze. in three time periods of 24, 48 and 72 hours from the time of venipuncture.

aim: the aim of this study was to determine the effect of clobetasol ointment with nitroglycerin ointment on the prevention of superficial phlebitis caused by cannulation. background: today, more than 80 to 90% of hospitalized patients receive intravenous treatment during their treatment, and more than 500 million peripheral venous catheters are placed annually, although cannulation provide numerous benefits in clinical setting, but because of its invasive feature, it can end in unpleasant outcomes such as phlebitis method: this clinical trial was conducted on 110 patients admitted to the surgical ward, in three groups of clobetasol, nitroglycerin, and control. the data collection tools included demographic information, information about intravenous treatment and phlebitis measurement scale. in the intervention groups, after venipuncture, 1.5 cm (about 2 g) of ointment was applied in the distal part of the angio catheter and the site was dressed with sterile gauze. in three time periods of 24, 48 and 72 hours from the time of venipuncture.

Eligibility criteria:
inclusion criteria: * must be older than 18 years old * must be in need of hospitalization at least 72 hours * does not state any previous allergic reaction to the ointments * does not use any types of drug that can hurts veins (chemotherapy drugs, diazepam. amiodarone, and....) exclusion criteria: * active infection * discharge from hospital sooner than 72 hours * displacement of cannula before 72 hours

Keywords: nitroglycerine clobetasol phlebitis
evaluation of protective effect of activated charcoal and probiotic against progression of chronic kidney disease

Conditions: Uremic Toxin

Summary: investigate the nephroprotective effect of activated charcoal and probiotic in limiting the progression of renal impairment in patients with chronic kidney disease and improving of renal function test and phosphate level. condition or disease: chronic kidney disease

chronic kidney disease (ckd) is characterized by a gradual decrease in the glomerular filtration rate (gfr) and proteinuria. ckd is a global health problem, and its incidence has been increasing. the estimated global prevalence of ckd is 8-14%. when kidney function deteriorates gradually, many metabolites accumulate in the body. these accumulated substances, termed as uremic toxins (uts), can result in adverse pathophysiological outcomes. uts can affect multiple organs and cause renal fibrosis, vascular calcification, anemia, peripheral arterial disease, adynamic bone disease, adipocyte dysfunction with insulin resistance, impaired immune system, and uremic pruritus. the pathophysiological mechanisms through which uts cause multiple organ damage are complex and not completely understood. these mechanisms may include inflammation, reactive oxidative stress, cellular transdifferentiation, impaired mitochondria function, intestinal barrier destruction, and changes in intestinal microbiota.

Eligibility criteria:
inclusion criteria: * patients with age more than 18 years old; * patients with ckd; * both genders will be included. exclusion criteria: * patient with age less than 18 years old; * inability or rejection to take activated charcoal or probiotic; * clinically unstable; * pregnant; * unlikely to adhere to study procedure (eg. due to cognitive limitations, severe psychiatric disorder or alcoholism).

Keywords: indoxyl sulfate
assessment the efficacy of curcumin local delivery gel in treatment of periodontitis in smokers

Conditions: Periodontitis

Summary: smokers usually respond less favourably to non-surgical periodontal treatment compared to non-smokers. numerous studies reported that smoker patients exhibited less reduction in probing depth and less gains in clinical attachment level values following scaling and root planing (kanmaz et al., 2021, alwithanani, 2023) several studies have proposed the use of adjunctive treatment approaches such as local/systemic antimicrobials and anti-inflammatory agents to improve the effects of basic periodontal therapy in smokers. however, no studies have been published evaluated the conventional management of topically delivered curcumin gel in conjunction with scaling and root planing demonstrating its ability to improve periodontal outcomes in smokers. meanwhile, some clinical trials indicate that local and systemic administration of curcumin can enhance the results of srp in periodontal treatment. local delivery allows higher concentrations of the active compounds in the diseased site and avoids possible adverse effects of systemic administration.

tobacco use increases the risk and progression of periodontitis by multiple factors including decreased gingival perfusion, which restricts nutrients and oxygen delivery as well as the removal of waste products. in addition, it affects the circulating levels of immune-inflammatory cells in gingival crevicular fluid, and affects the dysbiosis microbiota reducing the ability of the periodontium to repair. curcumin is an extract from the turmeric plant curcuma longa l. it has been shown potent anti-microbial, anti-carcinogenic, antiviral, antioxidant, and anti-inflammatory properties. in periodontitis, curcumin plays a pivotal role in anti-inflammatory properties, by inhibiting pro-inflammatory cytokines, reducing the prostaglandin biosynthesis, inhibiting the mrna and protein expression of cyclo-oxygenase-2, through down-regulation of nf-kb activation. meanwhile, some clinical trials indicate that local and systemic administration of curcumin can enhance the results of srp in periodontal treatment; local delivery allows higher concentrations of the active compounds in the diseased site and avoids possible adverse effects of systemic administration (pérez-pacheco et al., 2021, borgohain et al., 2023, chatzopoulos et al., 2023).

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with generalized periodontitis with stage ii 2. nonsurgical or surgical periodontal therapy in the last 3 months were considered as eligible for the study. 3. current smoker or smoker over the past 5 years. exclusion criteria: 1. presence of overhanging restorations, 2. antibiotics or any form of periodontal therapy in the previous 6 months. 3. history of systemic disease, cardiovascular diseases, diabetes mellitus, hypertension, bleeding disorders, hyperparathyroidism, and compromised medical conditions, pregnancy and lactation. 4. teeth with both endo-perio lesions. 5. patient on antibiotics within 3 months prior to the study.

Keywords: curcumin local delivery gel smokers periodontitis rct
dermaprazole cream for radiation dermatitis in head and neck cancer

Conditions: Cancer of the Head and Neck

Summary: in this study, the study team seek to conduct a pilot clinical study to evaluate the safety and efficacy of a reformulated proton pump inhibitor (ppi) cream (dermaprazole) in definitive head and neck cancer (hnc) patients.


Eligibility criteria:
inclusion criteria: * patients with head and neck malignancy (including radiation therapy to primary head cancers of any histology and/or neck lymphatics, excluding brain malignancies) * biopsy proven diagnosis of head and neck malignancy * planned to receive definitive chemoradiation of at least 66gy * age 18 years or older * eastern cooperative oncology group (ecog) performance status 0 - 2 * written informed consent * history and physical within 12 weeks of enrollment exclusion criteria: * prior head and neck radiotherapy * neoadjuvant chemotherapy * any serious medical condition or illness that would preclude the safe administration of the trial treatment including, but not limited to, active infection, symptomatic heart failure, unstable angina, psychiatric illness or social situations that would limit compliance with treatment * currently taking proton pump inhibitors. eligible if discontinues with physician approval. * lack of concurrent chemotherapy * open wound at time of simulation * known autoimmune, connective tissue, or skin disorder; or other theoretical radiosensitivity to include bullous pemphigoid, dermatomyositis, lupus of the skin and scleroderma
prognosis of bronchiectasis in children--a multicenter prospective cohort study

Conditions: Bronchiectasis

Summary: this prospective cohort study is designed to observe of the effect of intervention therapy on the long-term prognosis of children with bronchiectasis. the main purpose of the study was to evaluate the degree of deterioration of lung function, to observe and compare the quality of life, the time of pulmonary exacerbation, and the changes of lung image.

all enrolled patients are followed up for half a year, 1 years, 2 years, 3 years, 4 years, 5 years, while observation of pulmonary function, symptoms, signs, quality of life, the times of acute pulmonary exacerbation, and the changes of lung image are performed.

Eligibility criteria:
inclusion criteria:a included patient must be coincident at least one point of the four items of high-resolution computed tomography (hrct) manifestations. * internal bronchial diameter greater than the accompanying pulmonary artery. * lack of bronchial tapering * bronchi visible in the peripheral 1cm of lung * bronchial diameter greater than adjacent segmental bronchi exclusion criteria:subject will be excluded if she or he has one of the following * it is unable or doesn't agree to accept the follow-up process * undergoing trial for other medications or instruments.

Keywords: children prognosis
absorb gt1 japan pms

Conditions: Ischemic Heart Disease; Angina Pectoris; Coronary Artery Disease; Coronary Artery Occlusion; Myocardial Ischemia

Summary: the purpose of the surveillance is to know the frequency and status of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect efficacy and safety information for evaluating clinical use results.


Eligibility criteria:
inclusion criteria: * general percutaneous coronary intervention (pci) population. exclusion criteria: * no specific exclusion criteria.

Keywords: drug eluting bio-resolvable scaffold (brs) bio-resolvable scaffold (brs) real world
trial comparing two techniques of celiac plexus neurolysis for treatment of pain in carcinoma pancreas

Conditions: Pancreatic Cancer

Summary: coeliac plexus neurolysis (cpn) is a management option for pain control in carcinoma pancreas.cpn is conventionally performed by percutaneous technique with fluoroscopic guidance. endoscopic ultrasound (eus) is increasingly used for cpn as it offers a better visualization of the plexus. there are limited data comparing the two modalities.the patients are on follow-up for 6 months post neurolysis.

carcinoma pancreas patients with abdominal pain requiring daily analgesics for more than 4 weeks were included.we are randomising about 100 patients into two groups to undergo either of the two procedures, i.e. celiac plexus neurolysis by percutaneous technique or by endoscopic ultrasound guided technique.the pain scores have been recorded by visual analogue scale for an average follow-up of 6 months.

Eligibility criteria:
inclusion criteria: * all patients with carcinoma pancreas exclusion criteria: * patients below 18 years of age and who have not given consent

Keywords: carcinoma pancreas percutaneous celiac plexus neurolysis endosonography guided celiac plexus neurolysis